Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX + Tislelizumab + PLD for Resectable Gastric Cancer
NCT05536102Phase 2Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, doxorubicin in gastric adenocarcinoma, sponsored by Shanghai General Hospital. Started Sep 2022; status: recruiting.
02
Drugs
tislelizumabdoxorubicin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT05536102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05536102.